NAA25 Knockout Cell Lines

Gene: NAA25

Official Full Name: N-alpha-acetyltransferase 25, NatB auxiliary subunitprovided by HGNC

Gene Summary: This gene encodes the auxiliary subunit of the heteromeric N-terminal acetyltransferase B complex. This complex acetylates methionine residues that are followed by acidic or asparagine residues.[provided by RefSeq, Mar 2010]

Get A Quote

Products Background Case study

Products

Catalog Number	Product Name	Species	Gene	Passage ratio	Mycoplasma testing	Price
KO00018	NAA25 Knockout cell line （HeLa）	Human	NAA25	1:3~1:6	Negative	Online Inquiry

Background

NAA25 Gene Knockout Cell Lines represent a significant advancement in genetic research, specifically designed to facilitate the study of gene function and regulation. These cell lines are engineered using CRISPR/Cas9 technology to create precise gene knockouts of the NAA25 gene, which encodes for a crucial component involved in protein acetylation and regulation of various cellular processes. By eliminating the expression of this gene, researchers can gain insights into its role in cellular mechanisms, disease states, and potential therapeutic targets.

The key function of NAA25 Gene Knockout Cell Lines lies in their ability to mimic gene loss in a controlled environment, allowing for detailed analysis of downstream effects on cellular behavior and metabolic pathways. This is accomplished through techniques such as RNA sequencing, proteomics, and cell viability assays, enabling users to identify changes in gene expression and cellular functionality due to the absence of the NAA25 gene.

The scientific importance of these cell lines cannot be overstated; they provide invaluable tools for basic and applied research, including cancer biology, neurobiology, and developmental biology. Researchers can utilize these models to explore gene interactions, delineate signaling pathways, and investigate novel drug targets, thereby contributing to the advancement of personalized medicine and novel therapeutic approaches.

Unique advantages of NAA25 Gene Knockout Cell Lines include their reproducibility and consistency, yielding reliable data across experiments, which is often a challenge with other genetic models. Additionally, their compatibility with high-throughput screening methodologies makes them an attractive option compared to alternative systems that may require extensive time and resource investment.

For researchers and clinicians, investing in NAA25 Gene Knockout Cell Lines translates to enhanced experimental efficiency and groundbreaking discoveries. The capability to study gene loss in a highly controlled manner accelerates the pace of scientific inquiry and accelerates the transition from bench to bedside.

Our company prides itself on delivering high-quality biological products backed by extensive expertise in gene editing technologies, ensuring that our NAA25 Gene Knockout Cell Lines meet the highest standards for scientific research and innovation. By choosing our products, users are equipped with powerful tools that propel their investigations and enhance the understanding of complex biological processes.

Case study

NAA25 Gene Knockout Cell Lines for Breast Cancer Research

Research Focus

Investigate the role of NAA25 (N-alpha-acetyltransferase 25) in breast cancer progression and its potential as a therapeutic target using NAA25 gene knockout (KO) cell lines, with a focus on its impact on cell apoptosis, cell cycle regulation, and molecular signaling pathways.

Background

1. Breast Cancer and Unmet Targets

Breast cancer is the most common cancer in women worldwide, with a need for new therapeutic targets to improve outcomes. Genetic variants associated with breast cancer risk, such as rs11066150, have been linked to long non-coding RNAs, but the role of nearby genes like NAA25 remains unclear .

2. NAA25 as a Putative Oncogene

NAA25 encodes an auxiliary subunit of the N-terminal acetyltransferase B complex, which modifies proteins involved in cell cycle and apoptosis. NAA25 variants are associated with autoimmune diseases, but its role in cancer is uncharacterized .

3. Genetic Association with Breast Cancer

The SNP rs11066150, located in the NAA25 intron, is associated with breast cancer risk in Han Chinese women. NAA25 expression is upregulated in breast cancer tissues, suggesting a potential oncogenic role .

Solution

1. Generation of NAA25 KO Cell Lines

Method: CRISPR/Cas9 technology was used to generate stable NAA25 KO in breast cancer cell lines (T47D and MCF7). Short hairpin RNAs (shRNAs) targeting NAA25 were validated for knockdown efficiency, and KO was confirmed by RT-qPCR and western blotting .

Validation: NAA25 KO cells showed >70% reduction in NAA25 mRNA and protein levels compared to wild-type cells, with no off-target effects detected .

2. Functional Characterization of NAA25 KO Cells

Apoptosis Induction: Flow cytometry revealed a 2.3-fold increase in apoptotic cells in NAA25 KO lines vs. controls, with enhanced Annexin V/PI double-positive staining .

Cell Cycle Arrest: NAA25 KO cells exhibited a 40% increase in G2/M phase arrest, confirmed by PI staining and flow cytometry analysis .

Proliferation Inhibition: Colony formation assays showed a 60% reduction in clonogenic survival of NAA25 KO cells, indicating suppressed tumor growth potential .

3. Molecular Pathway Analysis

RNA Sequencing: Transcriptomic analysis of NAA25 KO cells identified 119 differentially expressed genes (DEGs), with enrichment in apoptosis pathways (e.g., TNF signaling) and downregulation of tumor-associated pathways (MYC, HIF1A, ERBB2) .

Validation: RT-qPCR confirmed upregulation of pro-apoptotic genes (IFIT2, NDRG1) and downregulation of HSPH1, a chaperone linked to cancer progression .

Conclusion

1. Mechanistic Insights

NAA25 promotes breast cancer progression by:

Suppressing Apoptosis: NAA25 KO activates TNF-mediated apoptotic pathways, increasing cell death .

Regulating Cell Cycle: NAA25 depletion arrests cells in G2/M phase, reducing proliferation .

Modulating Immune Response: NAA25 KO upregulates immune-related genes (e.g., IFIT2), potentially enhancing anti-tumor immunity .

2. Translational Significance

Biomarker Potential: High NAA25 expression in breast cancer tissues correlates with poor overall survival (OS), making it a promising prognostic biomarker. Patients with high NAA25 levels may benefit from targeted therapies aiming to reduce NAA25 expression .

Therapeutic Target: NAA25 KO sensitizes breast cancer cells to apoptosis, suggesting that NAA25 inhibitors could be developed as monotherapies or combined with existing chemotherapies to enhance efficacy. RNA-seq data further indicate that NAA25 knockdown suppresses tumor-associated pathways (e.g., MYC, HIF1A), supporting its role as a therapeutic target .

Immunotherapy Implications: The upregulation of immune response genes (e.g., IFIT2, NDRG1) in NAA25 KO cells suggests that NAA25 inhibition may enhance anti-tumor immune responses, potentially synergizing with immune checkpoint inhibitors .

3. Product Utility

NAA25 KO cell lines provide a robust model for:

Mechanistic Studies: Investigating NAA25-mediated regulation of apoptosis, cell cycle, and immune pathways in breast cancer.

Drug Screening: Identifying small molecules or biologics that mimic the effects of NAA25 depletion, such as compounds that induce apoptosis or arrest the cell cycle.

Combinatorial Therapy Testing: Evaluating the efficacy of NAA25 inhibitors in combination with chemotherapy, targeted therapies, or immunotherapies.

NAA25 Gene Knockout Cell Lines

Please note that all services are for research use only. Not intended for any clinical use.

Get a free quote

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.